The AID/APOBEC proteins are found in vertebrates and share the ability to insert mutations in DNA and RNA by deaminating cytidine to uridine. The first family member to be identified and characterized was the apolipoprotein B editing complex 1 (APOBEC1), a protein involved in the editing of the apolipoprotein B (ApoB) pre-mRNA 12. Further members were identified as DNA mutators. Activation-induced deaminase (AID) was revealed to be essential for the antigen-driven diversification of already rearranged immunoglobulin genes in the vertebrate adaptive immune system 3, and the APOBEC3s were shown to be involved in the restriction of retrovirus propagation in primates 45. The other members of the family, APOBEC2 and APOBEC4, have not yet been characterized. Table 1 lists the human AID/APOBEC paralogs; family members from other species are listed in Additional data files 1 and 2.

All the AID/APOBECs share the structural and catalytic backbone of the zinc-dependent deaminases, a large gene superfamily encoding enzymes involved in the metabolism of purines and pyrimidines (Figure 1). Of these deaminases, the tRNA adenosine deaminases (Tad/ADAT2) edit adenosine to inosine at the anticodon of various tRNAs in both eukaryotes and prokaryotes 6 and are thought to be the group from which the AID/APOBEC family originated (Figure 1). Indeed, as well as having functional and structural similarities to the AID/APOBECs 78, ADAT2 from trypanosomes seems to be able to deaminate cytidine in DNA 9.

The rise of the AID/APOBEC gene family appears to have been concurrent with the appearance of the vertebrate lineage and the evolution of adaptive immunity and AID is thought to be one of the ancestral family members (Figure 2). AID homologs able to trigger somatic hyper-mutation and class-switch recombination in B cells have been described in bony fish 1011, while bona fide AID homologs have been identified both in cartilaginous fish 10, which have immunoglobulin genes, and in the sea lamprey, a jawless vertebrate 12, which does not. The presence of AID in the lamprey is remarkable, as its system of 'adaptive immunity' is based not on immunoglobulins but on variable lymphocyte receptors (VLRs), a large family of proteins containing leucine-rich repeats, which undergo at least one round of diversification 1213. It will be interesting to know whether the sea lamprey AID homolog is involved in this process.

The gene structure for most AID/APOBECs genes includes five exons and is reminiscent of that of the DCDT (dCMP deaminases)/ADAT2 genes, in which the catalytic site is encoded in the third exon. In contrast, the other ancestral AID/APOBEC genes, namely APOBEC4 14 and APOBEC2 1516 (found in all jawed vertebrates, see Figure 2), have two and three exons respectively, with the coding sequence being mostly confined to the second exon. The few amino acids encoded by the first exon of APOBEC2 have no similarity to any known sequence. These observations provide clues to the overall evolution of the gene family: the absence of introns in the deaminase-like region of APOBEC4 and APOBEC2 suggests that these genes might be the result of early retrotranspositional events. Given the position of the sea lamprey deaminase genes (AID-CDA1 and CDA2) in the phylogenetic tree (see Figure 2), the APOBEC4 clade seems to have evolved independently from that of AID, while the clustering of APOBEC2 raises the possibility that AID provided its evolutionary scaffold. The phylogenetic relationships and gene structure of the later-evolved members of the family (APOBEC1 and APOBEC3) indicate that they have originated from sequential duplications of the AID locus.

The APOBEC1 locus derives from an inverted duplication of the AID locus on the same chromosome, located 40 kb away in most mammals. APOBEC1 homologs with the same genomic orientation are found in marsupials. In primates, owing to an inversion, the APOBEC1 locus is located approximately 1 Mb away from the AID locus 10. The main difference between APOBEC1 and the other AID/APOBEC genes is an extended coding sequence at its 3' end, whose significance has yet to be understood.

The APOBEC3 locus 4 originated after the divergence of the marsupial and placental lineages and is located in the region syntenic with human chromosome 22q13. A duplication event in the original 'placental' locus formed the two ancestral APOBEC3 genes, from which all other APOBEC3s have evolved through a complex history of gene duplications and fusions 1017. In some species, such as rodents, pigs and cattle, the two original genes have merged to form a single gene with a double zinc-coordinating domain, whereas in other species - primates, horses, bats, and felines - one of the two genes has been repeatedly duplicated to form an array of APOBEC3 genes. In primates in particular, the locus has rapidly expanded to seven genes. This rapid evolution of the APOBEC3 locus is thought to be the result of selective pressure on the APOBEC3s from their targets (retroviruses and retrotransposons) 1819.

Until very recently a crystal structure for a functionally characterized AID/APOBEC was not available and many of the structural features of this protein family have been ascertained by comparing their primary and secondary structure with the crystal structures of the functionally un-characterized APOBEC2 20 and of other zinc-dependent de-aminases, especially TadA from the Tad/ADAT2 family 21. The three-dimensional structure of the carboxy-terminal domain of APOBEC3G has now been published 22. This model shows the closeness between the APOBEC3G structure and those already known.

Like all zinc-dependent deaminases, the main structural feature of the AID/APOBECs is the domain responsible for their catalytic activity. In the amino-acid sequence, the signature for this domain is a H [AV]E-x_[24-36]-PCxxC motif (where x is any amino acid) (Figure 3). The histidine (H) and the two cysteines (C) coordinate a zinc atom and form the catalytic core of the deaminase (Figure 4). The cytidine is bound in this pocket and is deaminated through nucleophilic attack on the ammonium group on its carbon 4 by an activated water molecule (coordinated by the zinc atom) and the nearby glutamate, which acts as a proton donor.

The overall structure of the AID/APOBECs resembles that of other zinc-dependent deaminases. A series of five β strands forms the backbone of the molecule and α helices 2 and 3 hold the histidine and the cysteines in place and thus shape the catalytic pocket (Figure 4). Structural similarities with the Tad/ADAT2s in particular provide clues to the ability of the AID/APOBECs to deaminate cytidine. A comparison with the crystal structure of the bacterial TadA protein bound to its substrate 21 reveals the presence of a conserved loop (labeled in orange in Figure 4) that may play a role in substrate recognition 78. A serine-tryptophan-serine (SWS) motif (corresponding to SSS in APOBEC2) located before the PCxxC motif is necessary for catalytic activity 23 (labeled in pink in Figure 4). This structural arrangement forms a trough where the DNA strand could be positioned and recognized. Recognition of the substrate through these loops might explain the observation that different AID/APOBECs display sequence-context preferences in regard to the nucleotides immediately upstream of the cytidine to be deaminated (see for example 242526).

Dimerization/oligomerization of the AID/APOBECs has been reported, often occurring in an RNA-dependent manner (20272829 and references therein), but, in the case of AID and APOBEC3G, the quaternary structure does not seem to be necessary for the enzymatic activity (see for example 30).

The known functions of the AID/APOBECs revolve around their ability to get, more or less specifically, to their substrate and deaminate it. This means that, given the diverse roles that the AID/APOBECs perform, their cellular localization varies. Nonetheless, most AID/APOBECs are initially localized to the cytoplasm, a safe place considering their ability to mutate DNA.

AID was first discovered in 1999 in a subtractive hybridization screen comparing switch-induced and uninduced murine B lymphoma cells 3 and it is selectively expressed in activated B cells in germinal centers. Subsequent genetic experiments have revealed that AID is central to antigen-driven antibody diversification by class-switch recombination, somatic hypermutation, or gene conversion 313233. Genetic AID deficiency leads to Type 2 Hyper-IgM Syndrome 34, an immunodeficiency in which the inability to carry out class-switch recombination leads to the absence of antibodies other than those of the IgM class.

AID was initially thought to be an RNA-editing enzyme, but the discovery that it could mutate Escherichia coli DNA provided insight into its mechanism of action 35. The ability of AID to deaminate C to U in DNA is in keeping with the observation that there are two mutational phases during the somatic hypermutation process. Further confirmation of its role as a DNA mutator came from evidence that uracil DNA glycosylase (UNG), the enzyme responsible for the removal of uracil in DNA, acts downstream of AID 3637. In humans, mutations in the UNG gene cause Type 5 Hyper-IgM Syndrome 37.

Further studies revealed that AID targets single-stranded DNA (see for example 38) with a preference for cytidines within a sequence motif WRC (W is A or T; R is A or G) 2439. These observations are consistent with the presence of mutational hotspots at the immunoglobulin locus and the need for transcription (making single-stranded DNA available) for the antibody diversification processes to occur (40 and references therein). Following deamination to uracil, recruitment of the general DNA repair machinery results in both somatic mutation and the initiation of class-switch recombination (41 and references therein).

Whereas the function of AID is exerted in the nucleus, AID is predominantly cytoplasmic owing to the presence of a nuclear export signal (NES) at the extreme carboxyl terminus 424344. Accumulation of AID in the nucleus of murine B cells after ablation of the NES does not increase somatic hypermutation at the immunoglobulin locus, but causes an increase in non-physiologic hypermutation elsewhere in the genome 43. Intriguingly, the same region is deemed necessary for the successful initiation of class-switch recombination, but it is not clear whether there is a causal relation between nuclear export and this process 45. The presence of a weak nuclear localization signal (NLS) in the AID amino-terminal region has also been reported 424445.

APOBEC1 is expressed in the human small intestine and in the liver in rodents. It is responsible for ApoB pre-mRNA editing 12: deamination of cytidine 6666 changes a gluta-mine codon into a stop codon, thus generating a shorter form of ApoB (ApoB48). ApoB48 is the main component in the hydrophilic shell of the chylomicrons, the very low-density lipoproteins that transport triglycerides from the intestine to the tissues.

Like AID, APOBEC1 acts in the nucleus 46 and shuttles between cytoplasm and nucleus by virtue of an amino-terminal NLS and a carboxy-terminal NES 4748. APOBEC complementation factor (ACF) is known to target APOBEC1 and leads to suppression of the edited ApoB mRNA nonsense-mediated decay (see for example 49). Intriguingly, while the only phenotype in APOBEC1-deficient mice is the lack of ApoB mRNA editing (see for example 50), ACF deficiency is lethal 51. This, together with the conservation of the ACF gene throughout metazoans, could mean that AID/APOBECs were co-opted for ApoB mRNA editing only at a later stage in evolution, after the AID gene had been duplicated and the newly formed APOBEC1 was free to evolve.

While AID and the APOBEC3s have a loose sequence context preference for cytidine deamination, APOBEC1 is part of a complex that strictly recognizes a sequence 3' to the cytidine to be deaminated (the mooring sequence). After binding of the editing complex to an AU-rich motif, overlapping with the mooring sequence, APOBEC1 edits the C6666. The efficiency of editing is also mediated by a number of other cis-acting elements (52 and references therein). While there is no doubt on the physiological role for APOBEC1, its overexpression causes deamination of various RNAs in a promiscuous manner (see for example 5354). Intriguingly, APOBEC1 can also deaminate cytidine in DNA 2355, which might suggest additional functions for it, maybe more related to those of the other AID/APOBECs.

The APOBEC3s were first identified as paralogs of APOBEC1 by Jarmuz et al. 4, but attained the limelight when human APOBEC3G was identified as the factor involved in HIV restriction 5. HIV mutants lacking the viral infectivity factor (Vif) are non-infective in certain cell lines (so-called nonpermissive cell lines) but will propagate in others (permissive cell lines). APOBEC3G mRNA was isolated through a cDNA subtraction screen between CEM (nonpermissive) and CEM-SS (permissive) cells; its overexpression in CEM-SS cells reverses the permissive phenotype to nonpermissive 5.

APOBEC3G is packaged into the HIV virion and exerts its action on the nascent first DNA strand produced by reverse transcription in the target cell 5657585960. As a consequence, the viral genome is prevented from integrating into the cell's genome and those rare retrotranscripts that do succeed in integrating are heavily mutated and nonfunctional. APOBEC3G produces characteristic G to A mutations on the viral plus-strand cDNA, and in experimental conditions the mutation load on the viral genome can be as high as 3%.

In the presence of Vif, however, APOBEC3G is not able to prevent HIV propagation as it is ubiquitinated and targeted for proteasomal degradation - via a Cul5-SCF complex -when it interacts with Vif through its amino-terminal domain (see for example 6162). It is interesting to note that the interaction with Vif has shaped the evolution of APOBEC3G: a single amino-acid change among primate APOBEC3Gs confers resistance to other primate lentiviral Vif proteins (see for example 63).

Like APOBEC3G, all the primate APOBEC3 paralogs are able to restrict retroviruses with varying efficiency (Table 1). APOBEC3F, which has similar activity and expression pattern to APOBEC3G, preferentially deaminates cytidines, but in a different sequence context (see for example 252664). Interestingly, an analysis of HIV sequences hypermutated in vivo reveals a mutational bias toward the sequence preferences of APOBEC3G and F 2465.

Most cellular APOBEC3G is kept inactive in high molecular weight ribonucleoprotein complexes 282966. Its packaging into virions is mediated by both viral and cellular RNAs 676869707172, although the HIV Gag protein increases packaging efficiency 707273. For enzymatic activity to be displayed, the balance between high molecular weight and low molecular weight APOBEC3G complexes must be reversed 28 and, even after being packaged into virions, APOBEC3G must be freed by the action of RNase H during retrotranscription 66. Indeed, the avidity of APOBEC3G for RNA and its localization in mRNA-processing bodies in the cytoplasm (see for example 74) could serve as both regulatory and targeting mechanisms, and these properties might shed light on novel functions for APOBEC3s, such as involvement in microRNA regulation 75.

Given the similarities in the replication mechanisms, the APOBEC3s are able to restrict both retrotransposons and viruses with a reverse transcription step during their replication cycle (776 and references therein).

APOBEC2 1516, the only AID/APOBEC member until very recently for which a crystal structure was available 20, is expressed specifically in skeletal muscle and heart. It has proved the most elusive AID/APOBEC to characterize functionally, mainly because it has none of the enzymatic activities typical of its paralogs 15162377. APOBEC2 does not seem necessary for mouse development 77, but it is noteworthy that its appearance during metazoan evolution coincides with the evolution of slow/fast striated muscle and cardiac muscle 7879. Moreover, as with AID, the purifying selection driving the evolution of APOBEC2 at both the inter-species and intra-species level (bony fish have two copies of the gene) 718 suggests an evolutionary history constrained by function.

Very little is known about APOBEC4, the most recently identified AID/APOBEC 14. Its low sequence similarity to the other AID/APOBECs casts doubt on its ability to deaminate cytidine 7, but its ancestry might reveal novel links to the tRNA-editing enzymes and provide clues to the origin of the AID/APOBECs.

Despite the rapid progress in research on the AID/APOBECs, many questions remain. Apart from AID, the ancestral AID/APOBECs have not been functionally characterized. Moreover, while the enzymatic mechanisms of the characterized AID/APOBECs are now well known, the upstream and downstream events that mediate their action, and their involvement in other biological pathways are not yet known.

There have been a number of reports suggesting that the antiretroviral activity of the APOBEC3s could be dissociated from their ability to deaminate DNA (80 and references therein), but with a finer calibration of the experimental system, the only significant antiviral activity is likely to be due to the deaminase activity 818283. This highlights the difficulty in assaying the relevance of potential targets of APOBEC3s: the typical experimental system is based on transient overexpression of the enzyme together with the relevant retrovirus, followed by assessment of the infectivity of the viral particles in target cells. While this system can be used to test for novel APOBEC3 targets, it cannot be easily tuned to simulate the endogenous levels of the APOBEC3s. Thus the only known physiological target for endogenous APOBEC3s is HIV, and the G to A mutational bias observed in mobile elements 8485 is the only indication of an involvement of the APOBEC3s in inhibiting their transposition in vivo. New tools to study the targets of the APOBEC3s in a more physiological manner are needed.

As discussed above, retroviral inactivation by APOBEC3s is due to the resulting inability of the retroviruses (or other mobile elements) to be integrated into the target-cell genome 2657. While a role for DNA glycosylases in trashing the APOBEC3-modified viral genome was initially hypothesized, this is not the case 82838687, and other hypotheses need to be tested (for example, inefficient retrotranscription 88). But it will be difficult to prove this without being able to assay APOBEC3s at their endogenous levels.

Little is known of the mechanisms that lead AID to act specifically on the rearranged variable regions of immuno-globulin genes in antigen-activated B cells. Although cis-acting elements that might help determine specificity have been identified (for a review see 40), a trans-acting machinery is likely to play a major role in this targeting. Few proteins that interact with AID have been identified so far: MDM2, a regulatory protein shuttling between cytoplasm and nucleus 89 and replication protein A (RPA), a ubiquitous protein that binds single-stranded regions of DNA in DNA replication and repair 90. While this property of RPA makes its association with AID intriguing, its lack of specificity cannot explain the physiological targeting to the immunoglobulin locus. Moreover, murine AID needs to be phosphorylated in order to trigger antibody diversification and AID is associated with protein kinase A (PKA) 919293. Yet, AID phosphorylation is not specific to B cells 94, it is not required for the fish homolog to act 95, and phosphorylation-defective AID mutants show delayed activity in somatic hypermutation and its substantial decrease 92. These findings suggest that phosphorylation might be more related to AID modulation than to its targeting.

While the AID/APOBECs are powerful tools for improving the immune response, it is clear that their unique activity -inserting mutations in nucleic acids - represents a double-edged sword in cellular metabolism. Transgenic mice overexpressing APOBEC1 and AID develop tumors 9697, and the mutational context of C to T changes in genes commonly mutated in cancer is consistent with the action of these deaminases 24. In addition, the AID/APOBECs are widely expressed in cancer tissues and cell lines 42398.

It was known even before the identification of AID that a number of genes were mutated as a byproduct of antibody diversification processes and that mutations and aberrations in some of these genes were specific to cancers of the B-cell lineage. AID has subsequently been proved to trigger c-myc/Igh translocations (a common trait in Burkitt's lym-phoma) in Balb/c mice 99100101. Furthermore, expression of AID is needed in order to develop germinal-center-derived lymphomas in cancer-prone mice 102, and its aberrant expression might also have a role in the development of cancer (see for example 103).

While there is no experimental evidence for the involvement of the APOBEC3s in cancer, they were first identified in keratinocytes treated with PMA, a phorbol ester known to be a skin tumor promoter 104. Moreover, the induction of these mutators by viral infection 105 or antiviral pathways 106 could be the key to their role in cancer.

In the end, given that an association between the AID/APOBECs and the onset of cancer has been established, it needs to be ascertained whether this is due to stochastic events - unavoidable side effects of a mutational machinery -or if there are specific conditions that might induce aberrant function. This will only be achieved by an in-depth knowledge of the physiological roles of the AID/APOBECs.

Additional data is available online with this article. Additional data file 1 contains the alignment of the protein sequences used to calculate the phylogenetic tree shown in Figure 2. Additional data file 2 is a detailed version of the phylogenetic tree shown in Figure 2.